Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center, shared an article by Naval Daver, et al. on X:
“Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis | Led by Naval Daver and Hussein Abbas.”
Journal: Clinical Cancer Research.
Authors: Naval Daver, et al.
More posts featuring Naveen Pemmaraju.